Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 5/20 | 0.37 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.37 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.37 |
| ▸ | ADORA3 | P0DMS8 | 10/20 | 0.37 |
| ▸ | CRHR1 | P34998 | 3/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | GCGR | P47871 | 1/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5386324 | 0.80 | ADORA3 (0.37) | ADORA2AADORA3CRHR1TDP1HSD11B1 | |
| SCHEMBL5380161 | 0.79 | KMT2A (0.41) | ADORA2AADORA2BADORA1 | |
| SCHEMBL4840644 | 0.78 | CNR1 (0.40) | ADORA2AADORA2BADORA1CRHR1TDP1 | |
| SCHEMBL4840591 | 0.78 | CRHR1 (0.39) | ADORA3CRHR1TDP1GCGRHSD11B1 | |
| SCHEMBL4833246 | 0.75 | CNR1 (0.39) | CRHR1TDP1 | |
| SCHEMBL5384163 | 0.73 | NPC1 (0.44) | ADORA2AADORA2BADORA1 | |
| SCHEMBL4834043 | 0.72 | CRHR1 (0.43) | CRHR1 | |
| SCHEMBL4832926 | 0.71 | CNR1 (0.45) | CRHR1 | |
| SCHEMBL8261401 | 0.71 | CNR1 (0.45) | CRHR1 | |
| SCHEMBL4841263 | 0.70 | KDM4E (0.39) | CRHR1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7176210-B2 | Cannabinoid receptor ligands and uses thereof | PFIZER INC. (US) | 2007-02-13 | — | — | US | disclosed |
| US-7176210-B2 | Cannabinoid receptor ligands and uses thereof | PFIZER INC. (US) | 2007-02-13 | — | — | US | disclosed |
| US-7176210-B2 | Cannabinoid receptor ligands and uses thereof | PFIZER INC. (US) | 2007-02-13 | — | — | US | disclosed |
| US-20040157838-A1 | Cannabinoid receptor ligands and uses thereof | PFIZER INC | 2004-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040157838-A1 | Cannabinoid receptor ligands and uses thereof | CNR1, CNR2, GPR18 | ADORA2A 364/4885ADORA2B 469/4885ADORA1 397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.